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Umbilical cord transplants have emerged as an important therapeutic option for patients with leukemia and
lymphoma. A recent study in Nature Medicine highlights the potential and challenges of translating cell-
based therapies to the clinic.As the world awaits the much-anticipated
translational application of the recent
advances in embryonic and induced
pluripotent stem cell research, human
stem cell therapy has been a quiet reality
for over half a century for patients in
need of replacement of their blood-
producing system. Hematopoietic stem
cell (HSC) transplantation has been
increasingly refined since the ground-
breaking work of Donnall Thomas
(Thomas et al., 1957) in the late 1950s,
and currently, more than 3600 patients
undergo transplantation each year in
the U.S. HSC transplants often offer the
only chance for cure for patients with
leukemia, lymphoma, and other blood
disorders; while increasingly successful,
risks remain due to the conditioning
regimen, prolonged absence of immuno-
competent cells, and graft-versus-host
disease. Bone-marrow-derived HSCs, as
well as HSCs harvested from the periph-
eral blood stream following cytokine-
induced mobilization, have proven to be
widely effective therapeutic agents.
Umbilical cord blood (UCB), obtained
from the placental and umbilical vessels
after birth, has emerged as another
important source of HSCs over the last
two decades (Broxmeyer et al., 2009),
with more than 20,000 patients treated
worldwide to date. Currently, UCB is the
HSC source for almost 20% of all trans-
plants in the U.S. and for 50% in Japan.
UCB is a particularly important resource
when no matched HSC donor can be
found in the registry, as is often the case
for patients from ethnic minorities. UCB
HSCs have the dual advantage of being
readily available when needed and rela-186 Cell Stem Cell 6, March 5, 2010 ª2010 Etively immature, requiring less stringent
immunohistocompatibility matching than
adult-derived HSCs while providing an
overall more efficient immunoreconstitu-
tion. However, due to the physical volume
of the cord itself, the number of available
HSCs per UCB unit is approximately
10% of that commonly utilized in conven-
tional transplants. This results in delayed
HSC engraftment and recovery of white
blood cell number (28 days for UCB
versus 18–20 days for conventional
transplants), leaving the patient at
increased risk for infections. One attempt
to enhance HSC engraftment has been to
routinely transplant two UCB specimens
(Ballen et al., 2007); while this approach
boosts total HSC number infused, the
time for neutrophil recovery has not been
significantly affected.
To date, no treatment strategy has
been shown to enhance engraftment
and neutrophil recovery. A recent study
published in Nature Medicine (Delaney
et al., 2010) by Delaney et al. provides
a proof-of-concept to alleviate this unmet
clinical need. This work represents the
culmination of a translational effort that
began with the discovery of the NOTCH1
gene in human CD34+ stem/progenitor
cells 16 years ago (Milner et al., 1994).
Here, Delaney et al. used an ex vivo
culture strategy to significantly expand
UCB stem and progenitor cell types over
3 weeks through activation of the Notch
pathway by synthetic Delta ligand. The
authors first demonstrate the translational
potential of their earlier work, presenting
the results of xenograft transplants into
immunodeficient SCID mice, where ex
vivo culture with Delta increased thelsevier Inc.kinetics and efficacy of bone marrow
engraftment. By using a technically chal-
lenging limiting dilution xenotransplanta-
tion scheme, they calculated a 6.2-fold
enrichment in SCID-repopulating cells
following Delta exposure. Together, these
data clearly demonstrated that human
UCB cells were responsive to Notch acti-
vation through in vitro culture.
Delaney et al. then present the prelimi-
nary results of the first ten patients
enrolled in a phase I clinical trial using
the Delta in vitro culture protocol for UCB
transplantation. Here, the most impres-
sive finding is the significantly decreased
average time of neutropenia (defined by
an absolute neutrophil count of <500 cells
per ml) from 26 days to 16 days when
compared to patients receiving a standard
regimen, with the majority of the myeloid
recovery derived from the Delta-treated
UCB unit. Prolonged neutropenia has
been correlated with increased rates of
both bacterial and fungal infections, rep-
resenting one of the major complications
after HSC transplantation. These data
highlight the potential of the presented
culture method to significantly improve
clinical practice. While not presented
in detail here, once tested in a larger
cohort with long-term follow-up, the
dramatically improved neutropenia inter-
val should have clinically measurable
consequences, such as decreased hos-
pital stays, infectious complications, and
possibly long-term survival.
The current study also highlights the
challenges that exist when translating
basic stem cell biology into clinical prac-
tice, beginning with the selection of the
most appropriate culture containers and
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which are only hinted at in the manuscript.
These seemingly trivial issues could
significantly impair the results of clinical
trials and potentially prevent novel treat-
ment strategies from demonstrating
improvements. Additionally, there are
different measures of effectiveness
between preclinical and clinical studies:
the ability of HSCs to engraft marrow in
a long-term repopulation assay has long
been the gold standard in murine HSC
work and in fact is the functional definition
of HSCs. However, in clinical practice,
engraftment percentage, while elegantly
documenting functional efficacy, does
not directly translate into improved
patient care. Here, duration of neutrope-
nia and subsequent length of hospitaliza-
tion are much more relevant endpoints
and are rarely assessed in murine assays.
One of the biggest challenges that may be
faced by the Delta-mediated expansion
approach is the effect of the culture
conditions on the long-term viability and
function of HSCs: only 1 of 10 patients
had evidence of fully functional engraft-
ment of the Delta-cultured UCB unit, while
one other maintained only the myeloid
population, indicating impaired long-
term HSC function in the vast majority of
treated UCB specimens. The authors
themselves note this issue and speculate
that the culture altered the self-renewal
potential of the HSCs. It is currently poorly
understood how the culture conditions—
here, a mix of five cytokines—or the isola-
tion of the starting population, such as
CD34+ UCB cells, alters the differentiation
capacity and self-renewal potential of the
HSCs; however, the maintenance of stem
cells of any tissue source in culture,
including embryonic stem cell derived, is
a uniformly challenging problem. The
culture conditions that help expand the
cell population of interest may effectively
deprive the HSCs of microenvironmentalor niche components that are required
for optimal HSC persistence. Delaney
et al. use the biologically relevant Notch
pathway to enhance the proliferation of
phenotypic UCB HSCs; in this issue of
Cell Stem Cell (Butler et al., 2010),
members of the same group show that
one possible physiological source of
Notch in the bone marrow niche may be
endothelial cells (ECs). UCB units, har-
vested directly from their endothelial
niche, contain a mix of immature HSCs
and ECs; perhaps the presence of these
ECs contributes to the overall more effi-
cient immunoreconstitution seen with
UCB transplants. One can speculate
whether the addition of another factor as
the physiological ‘‘balancer’’ of Notch
signaling, possibly also EC derived, would
be able to help maintain these cells in
a functional HSC state during expansion.
In principle, three different approaches
to enhance engraftment and count
recovery after transplantation are pos-
sible: ex vivo culture to enhance HSC
and/or progenitor number, as done here
or with the use of insulin-like growth factor
(Zhang et al., 2008); short-term ex vivo
treatment of UCB prior to infusion, as in
recent studies using prostaglandin E2
(North et al., 2007) or an inhibitor of
CD26 (dipeptidylpeptidase IV) (Campbell
et al., 2007); or treatment of the recipient
to enhance the function of the hematopoi-
etic niche, such as parathyroid hormone
(Adams et al., 2007). Successful treat-
ment strategies may be combined to
maximize the benefit for the patients.
But ‘‘more’’ will not always be ‘‘better’’:
treatment of the transplant recipient with
leukemia or lymphoma may increase the
risk of stimulating cancer cells with the
transplanted HSCs, and enhanced differ-
entiation of progenitor cells to improve
short-term engraftment and cell recovery,
as shown by Delaney et al., may impair
the stem cell pool. Future studies areCell Stem Ceneeded to address these and other ques-
tions to improve safety and efficacy of
UCB transplants; Delaney et al. (Delaney
et al., 2010) have demonstrated that
clinical translation to enhance stem cell-
based therapies can be accomplished
and indicate the challenges for the field
on the road ahead.
ACKNOWLEDGMENTS
T.E.N. and W.G. receive patent royalties and
consulting fees from FATE Therapeutics, which is
currently testing the use of prostaglandin E2 to
enhance the efficacy of UCB transplants in a phase
I clinical trial.
REFERENCES
Adams, G.B., Martin, R.P., Alley, I.R., Chabner,
K.T., Cohen, K.S., Calvi, L.M., Kronenberg, H.M.,
and Scadden, D.T. (2007). Nat. Biotechnol. 25,
238–243.
Ballen, K.K., Spitzer, T.R., Yeap, B.Y., McAfee, S.,
Dey, B.R., Attar, E., Haspel, R., Kao, G., Liney, D.,
Alyea, E., et al. (2007). Biol. Blood Marrow Trans-
plant. 13, 82–89.
Broxmeyer, H.E., Cooper, S., Hass, D.M.,
Hathaway, J.K., Stehman, F.B., and Hangoc, G.
(2009). Bone Marrow Transplant. 44, 627–633.
Butler, J.M., Nolan, D.J., Vertes, E.L., Varnum-Fin-
ney, B., Kobayashi, H., Hooper, A.T., Seandel, M.,
White, I.A., Kobayashi, M., Witte, L., et al. (2010).
Cell Stem Cell 6, this issue, 251–264.
Campbell, T.B., Hangoc, G., Liu, Y., Pollok, K., and
Broxmeyer, H.E. (2007). Stem Cells Dev. 16,
347–354.
Delaney, C., Heimfeld, S., Brashem-Stein, C.,
Voorhies, H., Manger, R.L., and Bernstein, I.D.
(2010). Nat. Med. 16, 232–236.
Milner, L.A., Kopan, R., Martin, D.I., and Bernstein,
I.D. (1994). Blood 83, 2057–2062.
North, T.E., Goessling, W., Walkley, C.R.,
Lengerke, C., Kopani, K.R., Lord, A.M., Weber,
G.J., Bowman, T.V., Jang, I.H., Grosser, T., et al.
(2007). Nature 447, 1007–1011.
Thomas, E.D., Lochte, H.L., Jr., Lu, W.C., and
Ferrebee, J.W. (1957). N. Engl. J. Med. 257,
491–496.
Zhang, C.C., Kaba, M., Iizuka, S., Huynh, H., and
Lodish, H.F. (2008). Blood 111, 3415–3423.ll 6, March 5, 2010 ª2010 Elsevier Inc. 187
